Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine Combined With ATP in Moderate to Severe Depression
NCT05431413Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2020
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adenosine 5'-triphosphate in major depressive disorder (MDD) (3 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Hamilton Depression Scale at 4 weeks. Started Jan 2020; status: recruiting.
02
Drugs
adenosine 5'-triphosphate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05431413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431413.